You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output.
Click here to find out more.
X Demographics
Mendeley readers
Attention Score in Context
| Title |
Selection of Immunostimulant AS15 for Active Immunization With MAGE-A3 Protein: Results of a Randomized Phase II Study of the European Organisation for Research and Treatment of Cancer Melanoma Group in Metastatic Melanoma
|
|---|---|
| Published in |
Journal of Clinical Oncology, May 2013
|
| DOI | 10.1200/jco.2012.43.7111 |
| Pubmed ID | |
| Authors |
Wim H.J. Kruit, Stefan Suciu, Brigitte Dreno, Laurent Mortier, Caroline Robert, Vanna Chiarion-Sileni, Michele Maio, Alessandro Testori, Thierry Dorval, Jean-Jacques Grob, Juergen C. Becker, Alan Spatz, Alexander M.M. Eggermont, Jamila Louahed, Frédéric F. Lehmann, Vincent G. Brichard, Ulrich Keilholz |
| Abstract |
Active immunization against the tumor-specific MAGE-A3 antigen is followed by a few but impressive and durable clinical responses. This randomized phase II trial evaluated two different immunostimulants combined with the MAGE-A3 protein to investigate whether a more robust and persistent immune response could be associated with increased clinical benefit. |
X Demographics
The data shown below were collected from the profiles of 9 X users who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| United States | 3 | 33% |
| Mexico | 1 | 11% |
| United Kingdom | 1 | 11% |
| France | 1 | 11% |
| Belgium | 1 | 11% |
| Unknown | 2 | 22% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 5 | 56% |
| Scientists | 2 | 22% |
| Science communicators (journalists, bloggers, editors) | 2 | 22% |
Mendeley readers
The data shown below were compiled from readership statistics for 132 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Belgium | 1 | <1% |
| Unknown | 131 | 99% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Student > Ph. D. Student | 27 | 20% |
| Researcher | 23 | 17% |
| Student > Bachelor | 16 | 12% |
| Other | 9 | 7% |
| Student > Master | 9 | 7% |
| Other | 24 | 18% |
| Unknown | 24 | 18% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 34 | 26% |
| Agricultural and Biological Sciences | 29 | 22% |
| Biochemistry, Genetics and Molecular Biology | 15 | 11% |
| Immunology and Microbiology | 14 | 11% |
| Pharmacology, Toxicology and Pharmaceutical Science | 6 | 5% |
| Other | 6 | 5% |
| Unknown | 28 | 21% |
Attention Score in Context
This research output has an Altmetric Attention Score of 25. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 02 April 2024.
All research outputs
#1,535,435
of 25,373,627 outputs
Outputs from Journal of Clinical Oncology
#3,783
of 22,043 outputs
Outputs of similar age
#12,574
of 207,611 outputs
Outputs of similar age from Journal of Clinical Oncology
#38
of 278 outputs
Altmetric has tracked 25,373,627 research outputs across all sources so far. Compared to these this one has done particularly well and is in the 93rd percentile: it's in the top 10% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 22,043 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 21.0. This one has done well, scoring higher than 82% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 207,611 tracked outputs that were published within six weeks on either side of this one in any source. This one has done particularly well, scoring higher than 93% of its contemporaries.
We're also able to compare this research output to 278 others from the same source and published within six weeks on either side of this one. This one has done well, scoring higher than 86% of its contemporaries.